Teladoc Health (NYSE:TDOC) Price Target Cut to $25.00

Teladoc Health (NYSE:TDOC) had its target price reduced by stock analysts at Canaccord Genuity Group from $28.00 to $25.00 in a research report issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the health services provider’s stock. Canaccord Genuity Group’s price target suggests a potential upside of 87.55% from the stock’s current price.

Other analysts have also issued research reports about the stock. SVB Leerink initiated coverage on shares of Teladoc Health in a research report on Monday, February 26th. They issued a “market perform” rating and a $17.00 price objective on the stock. Citigroup reduced their target price on shares of Teladoc Health from $21.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, February 21st. Barclays reduced their target price on shares of Teladoc Health from $26.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, February 21st. Piper Sandler reduced their target price on shares of Teladoc Health from $30.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, February 21st. Finally, Cantor Fitzgerald started coverage on shares of Teladoc Health in a research note on Thursday, February 29th. They issued an “overweight” rating and a $22.00 target price for the company. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $22.00.

Teladoc Health Stock Performance

Shares of TDOC stock opened at $13.33 on Friday. The firm has a market cap of $2.26 billion, a price-to-earnings ratio of -9.95 and a beta of 0.94. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.47 and a current ratio of 3.54. Teladoc Health has a 52 week low of $12.85 and a 52 week high of $30.41. The firm’s 50-day simple moving average is $15.17 and its two-hundred day simple moving average is $17.80.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Thursday, April 25th. The health services provider reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.02). The company had revenue of $646.13 million during the quarter, compared to the consensus estimate of $637.31 million. Teladoc Health had a negative return on equity of 9.22% and a negative net margin of 8.47%. The business’s revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.37) EPS. As a group, equities analysts forecast that Teladoc Health will post -1.07 earnings per share for the current year.

Insider Activity at Teladoc Health

In other Teladoc Health news, CAO Richard J. Napolitano sold 3,765 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $54,667.80. Following the completion of the transaction, the chief accounting officer now owns 18,077 shares of the company’s stock, valued at approximately $262,478.04. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, EVP Andrew Turitz sold 6,190 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $89,878.80. Following the completion of the sale, the executive vice president now directly owns 39,429 shares in the company, valued at approximately $572,509.08. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Richard J. Napolitano sold 3,765 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $54,667.80. Following the sale, the chief accounting officer now owns 18,077 shares of the company’s stock, valued at $262,478.04. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 135,441 shares of company stock valued at $2,038,251. Corporate insiders own 1.63% of the company’s stock.

Institutional Investors Weigh In On Teladoc Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ICA Group Wealth Management LLC purchased a new position in Teladoc Health during the 4th quarter valued at $28,000. Hexagon Capital Partners LLC increased its position in Teladoc Health by 204.4% during the 4th quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock valued at $34,000 after purchasing an additional 1,065 shares during the period. RIA Advisory Group LLC purchased a new position in Teladoc Health during the 4th quarter valued at $36,000. GAMMA Investing LLC purchased a new position in Teladoc Health during the 4th quarter valued at $41,000. Finally, Principal Securities Inc. purchased a new position in Teladoc Health during the 4th quarter valued at $45,000. 76.82% of the stock is currently owned by institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.